Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of lenalidomide given in the post-transplant setting for a 12 month maintenance period. SECONDARY OBJECTIVES: I. To obtain preliminary estimates of the 1-year response rate, event-free and overall survival using this regimen. OUTLINE: This is a phase I, dose-escalation study of lenalidomide followed by a phase II study. PRE-CONDITIONING (patients with cluster of differentiation \[CD\]20+ non-Hodgkin lymphoma): Patients receive rituximab intravenously (IV) per standard of care. PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV twice daily (BID) and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1. AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0. MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide orally (PO) on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.